Open AccessComparative effectiveness of anti-fibrosis treatment in patients after HCV infection and in patients with non-alcoholic fatty liver disease (NAFLD)
Author(s) -
Nadiia Gavryliuk,
Ihor Hospodarskyy,
O. V. Prokopchuk,
O. M. Krekhovska-Lepiavko,
B. A. Lokay,
M. E. Havrylyuk
Publication year - 2021
Publication title -
journal of education, health and sport
Language(s) - English
Resource type - Journals
ISSN - 2391-8306
DOI - 10.12775/jehs.2021.11.02.022
Subject(s) - medicine , fatty liver , fibrosis , disease , gastroenterology , liver fibrosis , drug , hepatic fibrosis , pharmacology
Due to the high prevalence of NAFLD and CHC, these two pathologies will progress and contribute to the progression of fibrosis. Unfortunately, nowadays there is no single treatment strategy for such patients. That is why, in most cases a variety of treatment regimens on the base of different hepatoprotectors are prescribed. Instead, there is evidence that the use of some hepatoprotectors has no influence on fibrotic processes in the liver or can even exacerbate them. In order to study the antifibrotic effect of hepatoprotectors in patients with posthepatic fibrosis after HCV infection and in patients with NAFLD, we studied the results of prescribing the hepatoprotective drug bicyclol.